You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK — Castle Biosciences, a developer of genetic tests for skin cancer, said this week that it expects to sell roughly 3.3 million shares of its common stock at $14 to $16 apiece in its planned initial public offering.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.
This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.
Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.